文献速递产科母胎医学

普伐他汀、质子泵抑制剂、二甲双胍、微量营养素与生物制剂:子痫前期预防或治疗的新视野

Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia.
PubMed 文献 · Am J Obstet Gynecol · 2020-09-16

本文综述了子痫前期预防或治疗的新兴治疗药物。候选药物靶向氧化应激、抗血管生成因子及血管紧张素、一氧化氮和促炎通路,多采用药物重定位策略。普伐他汀最受关注,临床前研究显示其多效性可改善多种分子靶点并在动物模型中缓解子痫前期表型,早期临床试验提示其可能具有治疗活性。

要点

  • 普伐他汀是研究最广泛的候选药物,临床前及早期临床试验提示可能具有治疗活性。
  • 质子泵抑制剂、二甲双胍和柳氮磺吡啶具有临床前证据支持其多分子作用。
  • 多种天然化合物、单克隆抗体及siRNA技术等新型策略正在临床前或临床试验中评估。

核心结论

  • 若发现经证实能有效预防或治疗子痫前期的新药,将显著改善全球母婴健康。

研究设计与样本

  • 本文为综述,汇总了子痫前期预防或治疗候选药物的临床前与临床研究证据。

主要发现

  • 普伐他汀在临床前研究中显示多效性,可作用于多个分子靶点并在许多动物模型中缓解子痫前期表型。
  • 早期临床试验提示普伐他汀可能具有治疗活性,多项大型预防试验正在计划或进行中。
  • 质子泵抑制剂、二甲双胍和柳氮磺吡啶具有临床前证据表明其多分子作用可缓解子痫前期病理生理。
  • 许多天然化合物(如植物提取物和微量营养素)在临床前研究中显示出治疗子痫前期的潜力。
  • 靶向肿瘤坏死因子α、胎盘生长因子及siRNA沉默sFlt-1或血管紧张素原表达等新型分子靶向策略已被提出。

临床怎么用

  • 目前尚无经证实可预防或治疗子痫前期并改变临床实践的新药,普伐他汀等候选药物仍需等待大型预防试验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There has been increasing research momentum to identify new therapeutic agents for the prevention or treatment of preeclampsia, drugs that can affect the underlying disease pathophysiology. Molecular targets of candidate treatments include oxidative stress, antiangiogenic factors, and the angiotensin, nitric oxide, and proinflammatory pathways. The proposed treatments undergoing preclinical and clinical trial evaluation are thought to act on placental or endothelial disease or both. Most have adopted the pragmatic strategy of repurposing drugs. Of all the therapeutic agents proposed, pravastatin has received the most interest. There are preclinical studies showing that it has pleiotropic actions that favorably impact on multiple molecular targets and can resolve a preeclampsia phenotype in many animal models. An early phase clinical trial suggests that it may have therapeutic activity. Several large prevention trials are planned or ongoing and, when completed, could definitively address whether pravastatin can prevent preeclampsia. Proton-pump inhibitors, metformin, and sulfasalazine are other drugs with preclinical evidence of multiple molecular actions that could resolve the pathophysiology of preeclampsia. These agents are also currently being evaluated in clinical trials. There have been many recent preclinical studies identifying the potential of numerous natural compounds to treat preeclampsia, such as plant extracts and micronutrients that have potent anti-inflammatory or antioxidant activity. Recent preclinical studies have also proposed novel molecular-targeted strategies, such as monoclonal antibodies targeting tumor necrosis factor alpha, placental growth factor, and short interfering RNA technology, to silence the gene expression of soluble fms-like tyrosine kinase-1 or angiotensinogen. Other treatment approaches that have transitioned to human trials (ranging from single-arm to phase III trials that have been completed or are ongoing) include folic acid, nitric oxide donors (such as L-arginine), recombinant antithrombin III, digoxin immune antigen-binding fragment, and melatonin. There have been case series showing the removal of circulating soluble fms-like tyrosine kinase-1 may help stabilize the disease and prolong pregnancy. Interestingly, there are case reports suggesting that monoclonal antibody eculizumab (complement inhibitor) may have therapeutic potential. If new agents are discovered that are proven to be effective in preventing or treating preeclampsia, the potential to improve global maternal and perinatal health will be significant.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Tong S, Kaitu'u-Lino TJ, Hastie R, et al. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. Am J Obstet Gynecol. 2020. PMID: 32946849. doi:10.1016/j.ajog.2020.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。